We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Receptor-directed therapy of T-cell leukemias and lymphomas.
- Authors
Morris, John C; Waldmann, Thomas A; Janik, John E
- Abstract
T-Cell leukemias and lymphomas represent a less common and heterogeneous group of lymphoid neoplasms. Overall, they respond less well to chemotherapy and have a poorer prognosis than their B-cell counterparts. T-Cell tumors express a number of potential targets for receptor-directed antibody therapy; however, there is no available therapeutic monoclonal antibody for these diseases with comparable activity to that of rituximab in B-cell disorders. Despite this, alemtuzumab, a humanized anti-CD52 monoclonal antibody has demonstrated meaningful anti-tumor activity in a variety of T-cell malignancies. A number of other antibodies, modified antibodies and immunotoxins directed against targets such as CD2, CD4, CD5, CD25, CD30 and CD122 expressed on malignant T-cells are under investigation. The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed.
- Publication
Journal of immunotoxicology, 2008, Vol 5, Issue 2, p235
- ISSN
1547-6901
- Publication type
Journal Article
- DOI
10.1080/15476910802129661